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Abstract
Objective
To examine mortality and associated risk factors, including possible eﬀects of mild cognitive
impairment, imaging, and CSF abnormalities, in a community-based population with incident
parkinsonism and Parkinson disease.
Methods
One hundred eighty-two patients with new-onset, idiopathic parkinsonism were diagnosed
from January 2004 through April 2009, in a catchment area of 142,000 inhabitants in Sweden.
Patients were comprehensively investigated according to a multimodal research protocol and
followed prospectively for up to 13.5 years. A total of 109 patients died. Mortality rates in the
general Swedish population were used to calculate standardized mortality ratio and expected
survival, and Cox proportional hazard models were used to investigate independent predictors
of mortality.
Results
The standardized mortality ratio for all patients was 1.84 (95% conﬁdence interval 1.50–2.22, p
< 0.001). Patients with atypical parkinsonism (multiple system atrophy or progressive supra-
nuclear palsy) had the highest mortality. In early Parkinson disease, a mild cognitive impair-
ment diagnosis, freezing of gait, hyposmia, reduced dopamine transporter activity in the
caudate, and elevated leukocytes in the CSF were signiﬁcantly associated with shorter survival.
Conclusion
Although patients presenting with idiopathic parkinsonism have reduced survival, the survival is
highly dependent on the type and characteristics of the parkinsonian disorder. Patients with
Parkinson disease presenting with normal cognitive function seem to have a largely normal life
expectancy. The ﬁnding of a subtle CSF leukocytosis in patients with Parkinson disease with
short survival may have clinical implications.
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In Parkinson disease (PD), the second most common neu-
rodegenerative disorder, life expectancy is reduced.1 There
are, however, conﬂicting data regarding the size of, and spe-
ciﬁc factors accounting for the reduced survival in comparison
to the general population. Most studies of survival in PD have
been hospital-based or have used register-based case-ﬁnding
methods. These designs may produce biased results, through
underrepresentation of mild PD cases and lack of referral of
older patients to hospital clinics.2 There are also few studies
of the survival in unselected populations of patients with
new-onset idiopathic parkinsonism (including atypical
parkinsonism), rather than PD.
In PD, previous studies have found that a nontremor-
dominant phenotype, PD dementia (PDD), and early auto-
nomic dysfunction are associated with a shorter survival.1,3,4
The recently deﬁned diagnosis of mild cognitive impairment
in PD (PD-MCI)5 has rarely been studied in this regard.
Furthermore, the neurobiology of PD with short survival
(in terms of factors such as striatal dopamine depletion
patterns, CSF abnormalities, or APOE genotype) is not well
known.
Against this background, we assessed all-cause mortality and
associated risk factors in a population-based, Swedish cohort
of patients with incident, carefully diagnosed idiopathic par-
kinsonism, including PD. The patients underwent extensive
neurologic, neuropsychological, and laboratory testing as well
as multimodal neuroimaging and received standard, or if in-
dicated, advanced treatments by movement disorder neurol-
ogists during long-term follow-up.
Methods
Study population
All participants were part of a population-based incidence
study of unselected cases of new-onset idiopathic parkin-
sonism, from a deﬁned geographic catchment area of 142,000
inhabitants in northern Sweden.6 The local tradition is to refer
all patients with suspected PD to the Department of Neu-
rology at Umeå University Hospital (our department), which
is the only neurologic department in the area. To avoid se-
lection bias, and to make case identiﬁcation as complete as
possible, a population screening was performed throughmany
sources, including letters sent twice yearly to all health prac-
titioners asking for referral of all suspected cases with incident
parkinsonism. Eldercare institutions were surveyed by visits
(the largest institution) with an examination by neurologists
of all cases that were reported to have signs of parkinsonism,
or by interview (remaining institutions).
All patients were recruited to the study in the early motor
(drug-naive) phase, between January 1, 2004, and April 30,
2009. After exclusion of patients with secondary parkinsonism
(e.g., due to neuroleptic drugs or stroke) or dementia at
baseline (e.g., patients with dementia with Lewy bodies), 182
participants were included and followed prospectively. A di-
agnosis of PD, multiple system atrophy (MSA), or progressive
supranuclear palsy (PSP) required agreement among the
examiners (neurologists specialized in movement disorders)
that the clinical criteria for the diagnosis were fulﬁlled based
on the UK Parkinson’s Disease Society Brain Bank criteria7 or
criteria for MSA or PSP.8,9
At the latest follow-up (up to death or 8.5–13.5 years following
inclusion in alive patients), 143 patients were diagnosed with
PD, 13 with MSA, 18 with PSP, 4 as having unclassiﬁable
parkinsonism, and 4 did not have idiopathic parkinsonism
(ﬁgure 1). Autopsy conﬁrmed the diagnosis in 3 cases of PD
and 2 cases of PSP.
Standard protocol approvals, registrations,
and patient consents
All participants provided written informed consent. The study
was approved by the Regional Medical Ethics Board in Umeå,
Sweden, and was performed in accord with the Declaration
of Helsinki.
Clinical assessments
All participants were investigated at study entry (baseline)
and followed up prospectively with standardized clinical
examinations, including the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS), the modiﬁed Hoehn and Yahr Scale,
Mini-Mental State Examination (MMSE), and the 39-item
Parkinson’s Disease Questionnaire, at least yearly, as de-
scribed previously.10 We divided the baseline UPDRS scores
into subscores for tremor (sum of items 20 and 21) and
postural imbalance and gait disorder (PIGD; sum of items 13,
14, 15, 29, and 30) and classiﬁed the phenotype of PD as
tremor predominant, intermediate, or PIGD in accordance
with the DATATOP (Deprenyl and Tocopherol Anti-
oxidative Therapy of Parkinson’s Disease) trial analyses.11
Olfactory function was investigated by the 12-item Brief Smell
Identiﬁcation Test,12 global mobility by the Timed Up and
Go (TUG) test, which is the time it takes to rise up from
a chair, walk 3 m, and sit down again,13 and depression by the
Montgomery-Åsberg Depression Rating Scale.14 Severe
Glossary
Aβ42 = β-amyloid 1–42; CI = conﬁdence interval; DAT = dopamine active transporter; MCI = mild cognitive impairment;
MMSE =Mini-Mental State Examination;MSA = multiple system atrophy; PD = Parkinson disease; PDD = Parkinson disease
dementia; PIGD = postural imbalance and gait disorder; PSP = progressive supranuclear palsy; SMR = standardized mortality
ratio; TUG = Timed Up and Go; UPDRS = Uniﬁed Parkinson’s Disease Rating Scale.
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hyposmia is deﬁned by a score <4 on the Brief Smell Identi-
ﬁcation Test. A possible REM sleep behavior disorder was
deﬁned by a history of dream enactment behavior on
a screening questionnaire.
CSF analysis
At study entry, 99 of the patients with PD and 21 of the
patients with atypical parkinsonism agreed to CSF collection
by lumbar puncture, using standard procedures. CSF total
tau concentration was measured using a sandwich ELISA
(INNOTEST hTAU Ag; Fujirebio, Ghent, Belgium) con-
structed to determine all tau isoforms irrespective of
phosphorylation status.15 Tau phosphorylated at threonine
181 was measured by a sandwich ELISA (INNOTEST
PHOSPHO-TAU [181P]; Fujirebio).16 CSF β-amyloid 1–42
(Aβ42) levels were measured using a sandwich ELISA
(INNOTEST β-AMYLOID [1–42]; Fujirebio) constructed
to measure Aβ containing the ﬁrst and 42nd amino acids.17
CSF levels of α-synuclein were analyzed using a commercially
available α-synuclein human ELISA (KHB0061; Invitrogen,
Carlsbad, CA) according to instructions by the manufacturer.
Experienced, board-certiﬁed laboratory technicians per-
formed the CSF analyses using procedures approved by the
Swedish Board for Accreditation and Conformity Assessment.
Cells in the CSF were counted by automated ﬂow cytometry.
A subtle pleocytosis of mononuclear leukocytes was opera-
tionally deﬁned by counts ranging between 2 and 20 cells per
microliter. However, no patient had more than 10 cells per
microliter.
Dopamine active transporter imaging
Of the 182 patients enrolled in the study, 170 patients (93.4%)
underwent dopamine active transporter (DAT) imaging by
123I-FP-CIT (DaTSCAN; GE Healthcare BV, Eindhoven, The
Netherlands) SPECT. DAT imaging was done 3 hours fol-
lowing an IV bolus dose of 185MBq 123I-FP-CIT. Imaging was
done prior to commencement of medication at baseline. The
imaging protocol was done within the framework of a non-
proﬁt clinical trial (EU no. 2009-011748-20) and constituted
a substudy within the research project. Semiquantitative
analysis (based on regions of interest) and visual evaluation of
the DAT SPECT were done unbiased by any clinical in-
formation at all times. Normal reference values were derived
from an age-matched group of healthy controls participating
in the study, and reduction of DAT uptake in the patients with
PD was measured in percent and SDs of the normal values.
The most aﬀected side (left or right) was deﬁned by the
putamen and caudate that showed the largest reduction of
123I-FP-CIT uptake. The putamen and caudate were in-
vestigated separately. The imaging protocol, equipment, and
semiquantitative evaluation methods that were used have
been described earlier.18 Two diﬀerent SPECT cameras were
used during the course of the project; one brain-dedicated
SPECT camera (the Neurocam) was later substituted by
a multipurpose hybrid SPECT/CT (both General Electric,
Milwaukee, WI). Normal reference values were established
for both equipments.18,19 All PD, MSA, and PSP patients
fulﬁlling diagnostic criteria and who participated in the DAT
imaging (n = 163) had a pathologic scan.
Genetic testing
One hundred thirty-three of the patients with PD agreed to
DNA analysis by peripheral blood sampling. DNA was iso-
lated from peripheral blood using standard procedures. The
variations of interest (the e2/e3/e4 polymorphisms) in the
APOE gene were genotyped using TaqMan Assays-by-Design
(Applied Biosystems, Foster City, CA). The assay was per-
formed according to manufacturer’s instructions and analyzed
using the allelic discrimination function of the TaqMan 7900
HT Fast Real-Time PCR system (Applied Biosystems). Ge-
notype success rates of 100% were obtained. The patients
who declined all laboratory investigations (n = 10) were older
Figure 1 Flowchart of patients included in the study
Diagnosis was established according to clinical diagnosis
at the latest follow-up and confirmed by autopsy in 5
patients. MSA = multiple system atrophy; PSP = pro-
gressive supranuclear palsy.
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than the others (79.1 vs 70.5 years) and had slightly higher
UPDRS scores for motor dysfunction but were otherwise
comparable. All laboratory analyses were performed blinded
from clinical data.
Neuropsychology
Extensive neuropsychological testing, used for PD-MCI and
PDD20 diagnostics, was performed at baseline and after 1, 3, 5,
and 8 years. At baseline, the patients with PD could be divided
into patients with MCI (PD-MCI, n = 61) and patients
without PD-MCI (PD with normal cognition, n = 82). Be-
cause all cognitive domains had been covered in the test
battery throughout the study period, PD-MCI diagnoses were
applied according to Movement Disorder Society guidelines,5
using level 2 criteria.21 Patients were classiﬁed as having MCI
at baseline if (1) impaired in a minimum of 2 tests in one
domain (single-domain MCI) or in a minimum of one test in
2 diﬀerent domains (multiple-domain MCI), (2) impair-
ments were ≥1.5 SDs below mean of normative data, (3) self-
perceived cognitive decline was reported in a questionnaire
(e.g., the 39-item Parkinson’s Disease Questionnaire) and/or
directly by patient and/or family member, and (4) the patient
had no functional impairment in basic activities of living
(i.e., driving a car, social or personal care, medication man-
agement) due to cognitive impairment. The tests used for
MCI classiﬁcation were, for episodic memory: Free and Cued
Selective Reminding Test, Logical Memory and Paired As-
sociative Learning from the Wechsler Memory Scale, and
Brief Visuospatial Memory Test (total recall); for working
memory: Digit Span Forward and Digit Span Backward from
Wechsler Adult Intelligence Scale III; for attention: Trail
Making Test A and B; for language: Controlled Oral Word
Association and Boston Naming Test; for visuospatial func-
tion: the Benton Judgment of Line Orientation Test and
Pentagon Copying from MMSE; and for executive function:
Wisconsin Card Sorting Test–computer version 2, Mental
Control fromWechsler Memory Scale, and Category Fluency
(animals in 60 seconds). In the multivariable analysis of fac-
tors predicting mortality in PD, baseline neuropsychology
results were used. However, to investigate possible eﬀects of
incident dementia (of which there were no cases at baseline),
the neuropsychology results from the 3-year follow-up were
also analyzed in relation to mortality. Incident PDD and PD-
MCI were diagnosed at the 3-year follow-up on the basis of
previous test results, a documented decline, cognitive decline
reported by the patient and/or family member, and (for
PDD) by the occurrence of functional impairment in basic
activities of living caused by cognitive impairment. Structural
MRI and routine laboratory tests were performed to exclude
cognitive impairment due to other causes than PD-MCI
or PDD.
Mortality
We followed all surviving patients yearly for approximately 8.5
to 13.5 years, until August 31, 2017. The average time since
inclusion in all patients was 7.7 years. Although a few older
patients were followed by telephone, rather than visits, during
the last few years, the survival data were complete. A death
certiﬁcate, in which the cause of death was stated, was
obtained for 98 (90%) of all the fatalities in the cohort.
Statistics
Potential group diﬀerences in clinical variables at baseline
were examined by 1-way analysis of variance, Fisher exact test,
and Kruskal-Wallis test, and correlation between variables by
Person r and Spearman ρ, as appropriate. Post hoc contrasts in
analysis of variance are shown corrected for multiple com-
parisons using Tukey HSD (honestly signiﬁcant diﬀerence).
The age- and sex-speciﬁc standardized mortality ratio (SMR)
was calculated, stratiﬁed by clinical diagnosis and sex and, in
the patients with PD, by MCI status, by dividing the observed
number of deaths counted from baseline in each group by
the expected number of deaths in each group. The expected
numbers of deaths were calculated using the age- and sex-
speciﬁc oﬃcial Swedish National Statistics of 2004–2017
mortalities multiplied by the person-time from each group in
the study. Conﬁdence intervals (CIs) for the SMRs were
calculated to the 95% level using the Poisson distribution and
p values using the χ2 distribution. Life expectancies (antici-
pated mean remaining time to live) based on SMR were
calculated using a modiﬁed Gompertz function, as done
previously.22 Cox proportional hazard analysis was used to
investigate whether one or more covariates predicted mor-
tality in PD. A list of potential risk factors for mortality was
generated, including factors previously found predictive and
factors of neurobiological interest (biomarkers). To in-
vestigate dopaminergic denervation at baseline, DAT-uptake
ratios were normalized by average SDs above or below the
normal mean (i.e., z score) in order to equate the numerical
values derived from the 2 diﬀerent scanners that were used.
The number of mononuclear leukocytes in CSF was in-
vestigated as a continuous predictor variable in relation to
survival. The presence of a CSF leukocytosis was also in-
vestigated. For univariate comparisons, we controlled for
a false discovery rate of 0.05 by using the Benjamini-Hochberg
procedure, resulting in a signiﬁcance level of p < 0.017. Be-
cause age is strongly related to survival, all results were ad-
justed for age. Multivariable models were then developed
using age with clinical variables and age with biomarker var-
iables as predictors of survival. Variables signiﬁcantly associ-
ated with survival at the p < 0.2 level in the univariate models
were included, using a backward elimination procedure. If
variables were highly correlated, the variable with the lower
p value was included to avoid multicollinearity. The only ex-
ception was the PIGD score, which was correlated to TUG
results but chosen over the TUG test because of perceived
higher clinical usefulness. In the ﬁnal multivariable models,
only variables with p < 0.005 were included to avoid over-
ﬁtting of the model and to restrict the number of predictors
for ease of use in clinical practice. To avoid confounding
related to the heterogeneity of the diﬀerent parkinsonian
diseases, detailed prognostic models were developed only for
PD, except for the CSF protein markers, which were also
investigated in atypical parkinsonism. All statistical analyses
e2048 Neurology | Volume 91, Number 22 | November 27, 2018 Neurology.org/N
were performed using SPSS 23.0 (IBM Corp., Armonk, NY)
or R Statistical Software.
Data availability
Anonymized data can be obtained by request from any
qualiﬁed investigator for purposes of replicating procedures
and results.
Results
Survival in incident idiopathic parkinsonism
Clinical characteristics at baseline for the patients with idio-
pathic parkinsonism are shown in table 1. Survival data from
ﬁrst evaluation to death or end of the study were obtained for
all participants (ﬁgure 1). Of the 178 patients with idiopathic
parkinsonism, 109 (61.2%) died during follow-up. Seventy-
seven (53.8% of 143) of the deaths occurred in the PD group,
12 (92.3% of 13) in the MSA group, and 16 (88.9% of 18) in
the PSP group. The 4 patients with unclassiﬁable parkinson-
ism likely represent cases of late-onset PD but were excluded
from further analyses, as they did not fulﬁll speciﬁc diagnostic
criteria. The overall mean age at death was 82.0 years. Deep
brain stimulation or pumps for intestinal delivery of levodopa
were used or had been used by 12 (8.4%) of the 143 patients
with PD.
Survival was related to the age at the ﬁrst visit (hazard ratio for
death: 3.03 for each decade older, 95% CI 2.30–3.98, p <
0.001). However, when survival in patients with MSA or PSP
was analyzed separately from PD, the age at the ﬁrst visit was
not a signiﬁcant factor (p = 0.766). As a measurement of
global cognitive function, survival also correlated with the
baseline MMSE score after adjustment for age (1.19 times
higher hazard for death for each lower point, p = 0.006). The
SMR for the whole parkinsonism cohort was 1.84 (p < 0.001)
times higher than the comparable age and sex distribution-
standardized mortality of the Swedish population during the
years 2004 to 2017 (table 2).
The SMR for the patients with PD was 1.58 and 3.32 for the
patients with atypical parkinsonism (table 2). The patients
with PD had an age-adjusted hazard ratio for death of 0.43
(95% CI 0.27–0.67, p < 0.001) compared to the patients with
atypical parkinsonism. More speciﬁcally, the age-adjusted
hazard ratio for death in MSA was 2.76 (95% CI 1.48–5.15,
p = 0.001) and 1.42 (95% CI 1.08–1.88, p = 0.012) in
PSP compared to the patients with PD (ﬁgure 2). As shown
Table 1 Characteristics of participants at the first (baseline) visit
Variable
Parkinson
disease MSA PSP
Unclassified
parkinsonism p Value
No. of participants 143 13 18 4
Age, y 71.2 (9.8) 73.6 (9.6) 75.0 (7.1) 85.7 (7.5) 0.012b
Disease duration, y 1.8 (1.4) 1.9 (0.9) 2.1 (1.5) 2.6 (1.0) 0.670
Sex, M/F (% M) 85/58 (59) 8/5 (61) 8/10 (44) 2/2 (50) 0.648
Hoehn and Yahr, median (IQR) 2.0 (2.0–3.0) 2.5 (2.0–3.0) 2.5 (2.0–3.0) 3.0 (2.5–3.5) 0.009
UPDRS total, median (IQR) 35.0 (27.0–46.0) 37.0 (32.0–49.0) 35.0 (31.0–45.0) 50.5 (41.5–64.5) 0.283
UPDRS III, median (IQR) 26.0 (19.0–35.0) 23.0 (20.0–37.0) 26.5 (24.0–32.0) 35.0 (28.0–41.5) 0.541
Possible RBD, n (%) 15 (11) 2 (15) 0 (0) 0 (0) 0.286
MADRS, depression score 4.5 (3.7) 8.0 (7.4) 7.7 (9.4) 5.0 (0.0) 0.025
Smell test, no. correct 6.6 (2.7) 7.0 (3.3) 7.1 (2.3) 0.626
Freezing, ever, n (%) 95 (67) 9 (69) 13 (76) 4 (100) 0.508
Orthostatic blood pressure drop,a mm Hg 10.9 (18.8) 21.3 (22.2) 2.7 (15.0) 0.048c
MMSE score 28.5 (1.7) 29.0 (1.1) 27.9 (1.6) 27.3 (2.1) 0.181
MCI diagnosis, n (%) 61 (43) 3 (23) 14 (78) 3 (75) 0.007d
Abbreviations: IQR = interquartile range;MADRS =Montgomery-Åsberg Depression Rating Scale;MCI =mild cognitive impairment;MMSE =Mini-Mental State
Examination;MSA=multiple systematrophy; PSP = progressive supranuclear palsy; RBD=REMsleep behavior disorder; UPDRS=Unified Parkinson’sDisease
Rating Scale, Part III, is the motor function subscale.
The participantswere naive to dopaminergic treatment at this time. Values aremeans (SD) unless otherwise stated. Disease duration is the time fromonset of
first motor symptom, as recalled by the patient, to baseline.
a Systolic pressure difference after 3 minutes of standing. Post hoc comparisons, using Tukey honestly significant difference with the significance level of p <
0.05 to control for multiple testing, showed the following differences.
b Parkinson disease younger than unclassified parkinsonism.
c MSA more orthostatic than PSP.
d MCI more common in PSP than in Parkinson disease and than in MSA.
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in table 3, the most common cause of death was pneumonia,
but in many cases, the exact cause of death could not be
determined (e.g., patients who died alone in their homes).
Assuming the mean age of 71.7 years at baseline in idiopathic
parkinsonism, the expected survival in PD was 9.6 years, and
6.1 years in atypical parkinsonism.
Survival in PD
Although there was no sex diﬀerence in the hazard ratio for
death in the patients with PD, the SMR was higher in female
(2.09, i.e., 109% more cases of death in female patients with
PD than in the general female Swedish population) than in
male (SMR: 1.33) patients (table 2). The survival also cor-
related with cognitive status. Mortality in patients with PD
(both male and female) with normal cognition at baseline was
not signiﬁcantly diﬀerent from the general Swedish pop-
ulation, while it was increased in patients with PD-MCI
(SMR: 2.17; table 2). The patients with PD-MCI at baseline
had a 2.4 times higher age-adjusted hazard of death during
follow-up compared to the patients without MCI at baseline
(p < 0.001, table 4). Survival in PD also correlated with the
baseline MMSE score (1.17 times higher hazard for death for
each lower point, after adjustment for age, p = 0.011). Fewer
years of formal education was not associated with reduced
survival. Assuming the mean age of 71.2 years at baseline, the
expected survival in PD was 11.6 years without MCI and 8.2
years with MCI.
A baseline PD phenotype comprising MCI, freezing of gait,
a PIGD phenotype, hyposmia, high disease severity (mea-
sured by the total and Part III UPDRS scores), slowness in the
TUG test, and onset of dementia during the ﬁrst 3 years
predicted shorter survival (table 4 and ﬁgure 3, A–F) in the
univariate analysis. Tremor was uncorrelated to survival. The
patients with PD had a 38% lower DAT uptake in the puta-
men and a 24% lower DAT uptake in the caudate nucleus in
the most aﬀected hemisphere compared to healthy controls. A
neurobiological factor (biomarker) that predicted a shorter
survival in PD was reduced DAT uptake in the striatum,
particularly in the caudate nucleus (1.48 times higher hazard
for death for each SD of lower uptake), while the baseline CSF
protein concentrations of neurodegenerative markers and
APOE genotype were not predictive (table 4). Higher Aβ42
concentration in CSF was, however, moderately associated
with increased survival when the whole cohort of patients with
parkinsonian disorders was investigated (age-adjusted hazard
ratio: 0.99 per pg/mL, 95% CI 0.98–1.00, p = 0.048 in all
patients and 0.97 per pg/mL, 95% CI 0.95–1.00, p = 0.036 in
the patients with atypical parkinsonism). Furthermore,
a proportion of all patients with PD (13.1%) had a subtle
Table 2 Standardized mortality ratio in parkinsonism in relation to clinical diagnosis
Sex No. No. of events Expected SMR (95% CI) p Value
Idiopathic parkinsonism cohort, all cases
Female 73 48 21.3 2.25 (1.66–2.98) <0.001
Male 101 57 35.8 1.59 (1.21–2.06) <0.001
Total 174 105 57.1 1.84 (1.50–2.22) <0.001
Atypical parkinsonism
Total 31 28 8.4 3.32 (2.21–4.80) <0.001
Parkinson disease
Female 58 34 16.3 2.09 (1.45–2.91) <0.001
Male 85 43 32.4 1.33 (0.96–1.79) 0.077
Total 143 77 48.7 1.58 (1.25–1.98) <0.001
Parkinson disease with normal cognition
Female 37 17 10.8 1.57 (0.91–2.51) 0.085
Male 45 18 18.5 0.97 (0.58–1.54) 0.814
Total 82 35 29.3 1.19 (0.83–1.66) 0.341
Parkinson disease with MCI
Female 21 17 5.5 3.12 (1.82–4.99) <0.001
Male 40 25 13.9 1.80 (1.162–2.65) 0.005
Total 61 42 19.4 2.17 (1.56–2.93) <0.001
Abbreviations: CI = confidence interval; MCI = mild cognitive impairment; SMR = standardized mortality ratio.
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pleocytosis of mononuclear leukocytes (2–10 cells) in the
CSF. These patients had a signiﬁcantly worse prognosis
compared to the other patients (hazard ratio for death: 6.31,
p < 0.001; table 4), independently of adjustment for eryth-
rocytes. Given this ﬁnding, the CSF results were further
analyzed. There was a trend that a higher number of leu-
kocytes at baseline tended to correlate with higher CSF total
tau and phosphorylated tau concentrations (r = 0.24, p =
0.019 and r = 0.22, p = 0.028, respectively). There was no
evidence of CNS infection in any of the patients and there was
no diﬀerence in neurodegenerative marker or total protein
concentrations in the CSF between PD patients with a leu-
kocytosis and the other PD patients. However, the PD
patients with a CSF leukocytosis had a higher progression of
the UPDRS III scores at the 1-year follow-up (median 4-point
increase vs 3-point decrease, p = 0.007,Mann-WhitneyU test)
than the other patients with PD, despite using equal medi-
cation dosages (as measured by levodopa-equivalent daily
dose).
After excluding factors strongly correlated to each other and
including only strictly signiﬁcant factors (at the p < 0.005
level) in a multivariable model, older age at baseline, prevalent
mild cognitive impairment, higher PIGD score, hyposmia,
reduced DAT uptake in the caudate, and an inﬂammatory
reaction (leukocytosis) in the CSF were independent clinical
and biomarker predictors of reduced survival in PD.
Discussion
In this prospective, population-based cohort study involving
in-person examination of all participants, we evaluated the
prognosis of idiopathic parkinsonism and PD with respect to
mortality, stratiﬁed by factors related to MCI and clinical and
neurobiological characteristics. To avoid selection bias, we
included all patients with incident idiopathic parkinsonism in
the studied area, rather than only PD, and we explicitly di-
agnosed atypical forms of parkinsonism. Our results should,
therefore, provide information that is generalizable to the
“real-life” experience of the overall population with idiopathic
parkinsonism.
In line with the ﬁndings from several previous studies,23,24
patients with MSA and PSP had a markedly worse prognosis
than patients with PD. In the present cohort, the patients with
incident, atypical parkinsonism (i.e., MSA or PSP) were older
than in most previous, hospital-based studies,24–26 possibly
Figure 2 Survival in incident, idiopathic parkinsonism
(A) Lexis diagram showing follow-up of patients throughout the study. The “atypical parkinsonism” group comprises patientswith new-onsetMSA and PSP. (B)
Kaplan-Meier plot of survival in relation to diagnosis (for number at risk, see supplemental table e-1, links.lww.com/WNL/A762). MSA = multiple system
atrophy; PSP = progressive supranuclear palsy.
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because of the population-based design. Our results conﬁrm
the dire prognosis of these diseases in this cohort, with a rel-
atively high observed age at onset. In fact, age was not a sig-
niﬁcant predictor of survival in patients with MSA or PSP,
which is likely explained by the strong eﬀect on mortality
caused by these disorders themselves.
Recent studies have also, despite advances in modern treat-
ment, found a reduced life expectancy in PD.1 Similarly, we
found that the survival of patients with PD was reduced in
comparison with the general Swedish population during the
same years (SMR 1.58, p < 0.001). The SMR in most modern
PD mortality studies has been in the range of 1.5 to 2.7.1,2
Hence, the risk of death in the present study was in the lower
range. This may be a result of the population-based study
protocol (including patients with mild parkinsonism and explic-
itly diagnosing cases of atypical parkinsonism, that have a worse
prognosis) and the fact that all patients had access to compre-
hensive health care services throughout the disease course.
It is currently unclear why many patients with PD experience
shorter lifespans. In the present PD cohort, the excess mor-
tality occurred most clearly in female patients and in patients
with MCI (with pneumonia being the most common cause of
death). Data on the general Swedish population show longer
survival in women than in men. Therefore, a similar death rate
(i.e., a hazard ratio close to 1) between the sexes in the present
study, as well as in previous studies,27,28 may be interpreted to
indicate a worse than expected prognosis for female patients
with PD. In keeping with this, some previous PD studies have
explicitly reported a highermortality among female patients.29–31
The fact that life expectancy is reduced in PD compared to the
general population independently from comorbidities,32 and
the ﬁnding of a correlation between mortality and severity of
PD symptoms as measured by clinical scales,33,34 suggests that
disease-speciﬁc features (such as α-synuclein pathology) at
least partly account for the increased mortality. We found that
the increased mortality in PD correlated with core parkinso-
nian symptoms (with the notable exception of tremor) and
olfactory dysfunction, independently of age. The elevated
mortality in PD also correlated with the severity of striatal
DAT imaging deﬁcits, both in the putamen and in the caudate.
Our ﬁndings indicate that the neurodegenerative process in
PD, which is linked to nigrostriatal denervation, is in itself
associated with increased mortality. Of note, resting tremor in
PD has been found to only weakly correlate with striatal do-
paminergic denervation.35
In contrast, mortality was not increased in patients with PD
who did not have cognitive impairment at study entry (male
patients without MCI actually had an SMR below 1). The
ﬁndings underscore the importance of an early PD-MCI di-
agnosis, as deﬁned by the Movement Disorders Society.
There is evidence that PD is associated with lower risk of
some diseases, such as many cancers, and a lower risk factor
burden from tobacco smoking and arterial hypertension.36–39
In PD patients with normal cognition, who have a milder
disease phenotype, such diﬀerences could counterbalance
mortality increases caused by neurodegeneration. Further-
more, a lower level of education was not associated with in-
creased mortality. This may indicate that the higher mortality
in patients with poorer cognitive function was related to the
pathologic process leading to cognitive dysfunction, rather
than being explained by socioeconomic factors. In keeping
with this interpretation, a few previous studies have found
dementia in PD to be an independent risk factor for death.3,40
Of note, we found higher mortality in PD patients with more
severe caudal DAT-uptake deﬁcits. Imaging studies (including
an fMRI study of the same patients with PD as those in the
Table 3 Causes of death in parkinsonism in relation to clinical diagnosis
Variable PD MSA PSP p Value
Deaths/no. of participants 77/143 12/13 16/18 <0.001
Mean age at death (SD) 83.0 (6.3) 78.3 (11.0) 80.0 (7.1) 0.073
Mean survival, years from baseline to death (SD) 6.5 (3.0) 4.7 (2.8) 4.8 (1.9) 0.031
Pneumonia 15 (19.5) 3 (25.0) 7 (43.8) 0.116
Dementia 2 (15.6) 0 0 0.085
Unknown 9 (11.7) 0 2 (12.5) 0.451
Heart infarction 7 (9.1) 1 (8.3) 1 (6.3) 0.934
Cancer, all types 6 (7.8) 2 (16.7) 1 (6.3) 0.556
Heart failure 4 (5.2) 2 (16.7) 0 0.159
Other causes 24 (31.2) 4 (33.3) 5 (31.3) 0.989
Abbreviations: MSA = multiple system atrophy; PD = Parkinson disease; PSP = progressive supranuclear palsy.
Data are n (%) unless otherwise stated. In 2 further patients with PD, pneumoniawas determined to have contributed to death in combinationwith sepsis and
renal failure, respectively. Difference in cause of death was calculated by χ2 analysis.
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Table 4 Early predictors of mortality in Parkinson disease
Variable, at baseline Observed range
Adjusted only for age Multivariable clinical model
HR (95% CI) p Value HR (95% CI) p Value
Age 39.7 to 90.0 y 1.11 (1.07–1.16) <0.001
Duration, since first symptom 0.2 to 7.5 y 0.93 (0.81–1.08) 0.366 — —
Sex F vs M 1.03 (0.65–1.63) 0.909 — —
UPDRS total score 8 to 81 1.03 (1.01–1.05) 0.001c — —
UPDRS III subscore 5 to 62 1.03 (1.01–1.05) 0.003c — —
PIGD score 0 to 12 2.61 (1.64–4.17) <0.001c 3.25 (1.75–6.05) <0.001
Tremor score 0 to 12 0.66 (0.32–1.35) 0.255 — —
Freezinga 0 to 3 2.17 (1.40–3.36) <0.001c — —
Fallinga 0 to 2 0.90 (0.45–1.79) 0.753 — —
Dysphagiaa 0 to 2 1.80 (1.02–3.21) 0.044 — —
Body mass index 19.2 to 36.5 kg/m2 1.01 (0.94–1.09) 0.800 — —
Severity of hyposmia (correct
answers on B-SIT)
0 to 12 0.83 (0.75–0.92) <0.001c 0.84 (0.75–0.93) <0.001
Timed Up and Go test 4.0 to 41.0 s 1.11 (1.07–1.15) <0.001c — —
Previous smoker ever vs never 1.54 (0.94–2.51) 0.081 — —
MADRS, depression score 0 to 18 1.02 (0.95–1.09) 0.529 — —
Years of education 6 to 30 1.01 (0.93–1.10) 0.780 — —
Mild cognitive impairment yes/no 2.38 (1.47–3.84) <0.001c 1.81 (1.04–3.14) 0.035
Dementia within first 3 y yes/no 1.94 (1.12–3.34) 0.017c — —
Orthostatic blood pressure dropb −26 to 77 mm Hg 1.01 (0.99–1.02) 0.425 — —
Biomarkers
Biomarker
model
Age 43.6 to 86.8 y 1.17 (1.11–1.23) <0.001
APOE «4 genotype 0 to 2 e4 alleles 1.14 (0.71–1.83) 0.593 — —
CSF Aβ42, pg/mL 249 to 1,373 ng/L 0.99 (0.98–1.01) 0.377 — —
CSF t-tau, pg/mL 81 to 1,053 ng/L 1.01 (0.99–1.02) 0.240 — —
CSF p-tau, pg/mL 17 to 129 ng/L 1.08 (0.95–1.23) 0.255 — —
CSF α-synuclein, pg/mL 323 to 2,179 ng/L 1.02 (0.95–1.09) 0.594 — —
Inflammatory reaction in CSF yes/no 6.31
(3.04–13.12)
<0.001c 5.59 (2.67–11.71) <0.001
CSF leukocytes, mononuclear cells 0 to 10 (count/μL) 1.28 (1.12–1.46) <0.001c — —
DAT uptake, most affected putamen −5.16 to −0.38 0.60 (0.44–0.82) 0.002c — —
DAT uptake, most affected caudate −4.72 to 0.14 0.67 (0.53–0.85) 0.001c 0.81 (0.61–1.06) 0.132
Abbreviations: Aβ42 = β-amyloid 1–42; B-SIT = Brief Smell Identification Test; CI = confidence interval; DAT = dopamine active transporter; HR = hazard ratio;
MADRS = Montgomery-Åsberg Depression Rating Scale; PIGD = postural imbalance and gait difficulty; p-tau = phosphorylated tau; t-tau = total tau; UPDRS =
Unified Parkinson’s Disease Rating Scale.
HRs formortality in patientswith Parkinson disease (n = 143), within 8.5 to 13.5 years. Themiddle 2 columns showunivariate association but, for clarity, values
are shown after adjustment for age.
a Assessed by UPDRS.
b The systolic pressure difference after 3 minutes of standing. Inflammatory reaction in CSF is defined by a subtle pleocytosis (2–10 mononuclear cells/μL).
c Significant prior to inclusion in the multivariable model.
Neurology.org/N Neurology | Volume 91, Number 22 | November 27, 2018 e2053
Figure 3 Survival in Parkinson disease in relation to phenotype
Kaplan-Meier plots of survival in patients with Parkinson disease (n = 143) in relation to clinical and neurobiological phenotype at baseline (except panel B,
which is related to phenotype at 3 years). Severe hyposmia is defined by a B-SIT score <4. All variables (A–F) were significantly related to survival at the p <
0.001 level (log rank) except the tremor or PIGD/intermediate variable (C), which was significant at the p = 0.004 level (for number at risk, see supplemental
table e-2, links.lww.com/WNL/A762). B-SIT = Brief Smell Identification Test; PIGD = postural imbalance and gait disorder.
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present study) have shown that dopamine denervation in the
caudate nucleus in PD correlates with cognitive deﬁcits.41,42
A positive APOE e4 carrier status or α-synuclein, Aβ42, and
total tau or phosphorylated tau concentrations in CSF were
uncorrelated with PDmortality. However, the number of CSF
samples may have made our study underpowered for
detecting such diﬀerences. The diﬀerence compared to the
ﬁndings in a recent neuropathologic study43 could also relate
to the fact that the present investigation used a more homo-
geneous disease group (PD). When CSF samples from all
patients with idiopathic parkinsonism were included, a lower
Aβ42 concentration was associated with shorter survival. This
may indicate that Alzheimer disease–type pathology is a pre-
dictor of reduced survival in parkinsonian disorders in gen-
eral,43 mainly in MSA and/or PSP.
The ﬁnding of a low-grade inﬂammatory reaction in the CSF
of 13.1% of the patients with PD was strongly related to
a reduced survival (with a 6.31 times increased hazard for
death). An increase of proinﬂammatory cytokines in the CNS
and an inﬂammatory, hyperreactive state in circulating mon-
ocytes has previously been shown in PD.44,45 Two large,
observational studies have also found a lower risk of PD as-
sociated with the use of nonsteroidal anti-inﬂammatory drugs
in the general population.46,47 Taken together, our ﬁndings
might suggest a triggered immune system, responding to the
presence of abnormal, misfolded proteins in PD patients with
short lifespans, possibly contributing to disease progression.
The shorter lifespans in patients with a CSF leukocytosis
indicate a rationale for further investigating immunomodu-
lation to reduce PD mortality.
The possibility of uncontrolled confounding factors and the
fact that neuropathologic diagnosis at autopsy of the nervous
system was obtained in only 5 of 109 deaths are limitations of
the study. Several studies have reported that neuropathologic
conﬁrmation of a clinical diagnosis of idiopathic PD ranges
from 65% to 93%,48 although the accuracy is higher in expert
centers.49 In addition, no autopsy examinations were per-
formed in any of the MSA cases. While acknowledging the
limitations of a clinical diagnosis, the risk of incorrect di-
agnosis was nonetheless minimized by the long follow-up
periods and the ﬁnding of pathologic uptake on DAT imaging
in all of the examined patients. Even so, the results, especially
the CSF ﬁndings, need to be conﬁrmed by future studies. Our
study also has several strengths, including a population-based
design, a high proportion of patients who were examined
using a multimodal research protocol, and prospective follow-
up for up to 13.5 years.
The present study shows that patients with incident parkin-
sonism have reduced survival but that the survival is highly
dependent on the type and characteristics of the parkinsonian
disorder. Early MCI in PD is an important predictor of the
prognosis. The ﬁnding of a low-grade immune reaction in the
CSF of patients with PD who have short survival may have
important clinical implications and therefore merits further
investigation.
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